Remove 2022 Remove FDA Remove Pharmaceutical Companies
article thumbnail

Grail plans FDA filing for cancer blood test after new trial

pharmaphorum

Skip to main content Friday 20 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

FDA 71
article thumbnail

FDA Approvals: September 2022 Recap

Digital Pharmacist

CDER relies on its understanding of science and regulatory procedures to support and provide advice to pharmaceutical companies in testing and manufacturing, to then bring these new therapies to the market to aid patients and their health. Date of Approval: 9/30/2022. Date of Approval: 9/29/2022.

FDA 75
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Mounjaro generic availability, cost, and more

The Checkup by Singlecare

Mounjaro (tirzepatide) is a brand-name prescription medication that is approved by the Food and Drug Administration (FDA) to improve blood sugar levels in people with Type 2 diabetes. The FDA recently approved generic versions of two other GLP-1s , Victoza (liraglutide) and Byetta (exenatide). Is there a generic for Mounjaro?

article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

IVRHA 2022: Exhibiting pioneers of medical XR

pharmaphorum

Over the past five years, medical XR companies that were smaller start-ups have evolved into multimillion-dollar enterprises, partnering with pharmaceutical companies to supply digital therapeutic solutions using 3D immersive technology. In 2021, the behavioural health company and Sumitomo Dainippon Pharma Co.

article thumbnail

Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen

pharmaphorum

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Caris swells its planned IPO, seeking $5.7bn valuation

pharmaphorum

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)